Ads
related to: otezla patient information pdf- Safety & Side Effects
Get The Facts About COSENTYX®
& Find Answers To FAQs Here.
- How To Inject COSENTYX®
See Videos & Resources To
Help Make Injections Easier.
- Patient Support Program
Learn About A Free
Support Program For COSENTYX®.
- COSENTYX® FAQs
Get The Facts And Learn More
About The COSENTYX® Experience.
- COSENTYX® Connect
Sign Up Today To Get Info
On Patient Support Services.
- COSENTYX® Still Working
Learn How COSENTYX® Is Still
Working With Cyndi & Michelle.
- Safety & Side Effects
Search results
Results From The WOW.Com Content Network
Apremilast, sold under the brand name Otezla among others, is a medication for the treatment of certain types of psoriasis and psoriatic arthritis. [4] The drug acts as a selective inhibitor of the enzyme phosphodiesterase 4 (PDE4). [ 4 ]
The majority of patients with PsA experience peripheral joint involvement. [5] Pain, swelling, or stiffness in one or more joints is commonly present in psoriatic arthritis. [ 5 ] Psoriatic arthritis is inflammatory, and affected joints are generally red or warm to the touch. [ 5 ]
In August 2020, Amgen, Takeda, and AbbVie, as part of a COVID-19 research and development (R&D) alliance, announced the first patients enrolled in the I-SPY COVID clinical trial. The trial evaluated the efficacy of Otezla and two other medicines in severely ill, hospitalized COVID-19 patients who required high-flow oxygen. [158]
[24] [25] It was approved by the FDA on December 14, 2016 under the brand name Eucrisa for the treatment of mild-to-moderate atopic dermatitis (eczema) in patients 2 years of age and older. [26] Caffeine is a weak, non-selective PDE inhibitor. [27] A metabolite of caffeine, theophylline, is a more potent PDE inhibitor. [27]
Apremilast (Otezla, Celgene) is an oral small-molecule inhibitor of the enzyme phosphodiesterase 4, which plays an important role in chronic inflammation associated with psoriasis. [ 110 ] It has been theorized that antistreptococcal medications may improve guttate and chronic plaque psoriasis; however, limited studies do not show that ...
Zasocitinib (TAK-279, NDI-034858) is a drug which is an orally active, highly selective, allosteric tyrosine kinase 2 (TYK2) inhibitor.It has been researched for various inflammatory conditions including psoriasis, psoriatic arthritis and Crohn's disease.
Ads
related to: otezla patient information pdf